Stryker just rolled out its next-generation InThrill Thrombectomy System, and it’s turning heads in the medical community.

Explore Penumbra's Q2 2025 earnings highlights, featuring 13.4% growth, U.S. thrombectomy success, RUBY XL launch insights, and updated revenue guidance.

Inari Medical, now part of Stryker, announced the launch of its next-generation InThrill thrombectomy system. According to ...

Inari Medical — now part of Stryker (NYSE: SYK) + — today announced the launch of its next-generation InThrill thrombectomy system. The company describes InThrill as the first and only purpose-built ...

Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when ...

A groundbreaking study from the University of Cambridge reveals a new drug that can significantly reduce brain damage caused ...

Penumbra Inc (PEN) reports a 13.4% revenue increase, driven by US thrombectomy success, while navigating international ...

Key Points Penumbra topped analyst forecasts with $339.5 million in GAAP revenue and $0.86 non-GAAP EPS, driven by double-digit U.S. thrombectomy growth. Gross margin (GAAP) expanded sharply to 66.0%, ...

Catheter system designed to treat blocked or damaged leg veins that have previously been stented and fail to return blood ...

Penumbra’s U.S. thrombectomy business was the standout performer, with revenue jumping 22.6% YoY to $188.5 million. The company’s U.S. venous thromboembolism (VTE) revenue showed particularly strong ...

A potentially life-saving stroke treatment will be on offer around the clock in Lancashire by early next year at the latest, ...